Wall Street Zen Begins Coverage on Trevena (NASDAQ:TRVN)

Wall Street Zen began coverage on shares of Trevena (NASDAQ:TRVN) in a report published on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Trevena Stock Performance

Shares of TRVN stock opened at $1.06 on Thursday. Trevena has a fifty-two week low of $0.95 and a fifty-two week high of $10.92. The firm has a market cap of $1.02 million, a P/E ratio of -0.02 and a beta of 0.87. The business’s 50 day moving average price is $1.22 and its 200-day moving average price is $1.52.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.